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a Department of Community Medicine and Social Healthcare Science, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-
0017, Japan
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c Analytical Center, Kobe Pharmaceutical University, 4-19-1 Motoyamakitamachi, Higasinada-ku, Kobe 658-8558, Japan
d Division of Biochemistry, Faculty of Pharmaceutical Sciences, Himeji Dokkyo University, 7-2-1 Kamiono, Himeji 670-8524, Japan
e Division of Medical Economics, Faculty of Pharmaceutical Sciences, Himeji Dokkyo University, 7-2-1 Kamiono, Himeji 670-8524, JapanThe authors regret that a phrase, “of exon 7”, was mistakenly omitted from the second paragraph of the Introduction section.
The second paragraph should be as follows: “The survival motor neuron genes SMN1 (telomeric SMN) and SMN2 (centromeric SMN)
have been identiﬁed as candidate SMA-causing genes at chromosome 5q11.2–13.3 [2]. SMN1 and SMN2 are largely identical, but nu-
cleotide þ6 of exon 7 in the coding region is a C in SMN1 and a T in SMN2, though these are synonymous and do not result in an amino
acid change. However, SMN1, but not SMN2, is now recognized as an SMA-causing gene, because SMN1 is completely deleted in more than
90% of SMA patients [3] and deleteriously mutated in the remaining patients [4].”
The correction above does not affect the results and conclusions of the paper.
The authors would like to apologise for any inconvenience caused.x.doi.org/10.1016/j.bbrep.2015.12.005
08/& 2016 The Authors. Published by Elsevier B.V. All rights reserved.
of original article: http://dx.doi.org/10.1016/j.bbrep.2015.10.012
esponding author at: Division of Epidemiology, Department of Community Medicine and Social Healthcare Science, Kobe University Graduate School of Medicine,
usunoki-cho, Chuo-ku, Kobe 650-0017, Japan.
ail address: nishio@med.kobe-u.ac.jp (H. Nishio).
